There were no differences in levels of NUCB2/nesfatin-1 among each phenotypes of MS (Clinically isolated syndrome, relapsing-remitting MS, Primary progressive MS, Secondary progressive MS). This evidence concerns the gene NUCB2 and myeloid sarcoma.